CD19 and systemic sclerosis: Longitudinal analysis of peripheral blood mononuclear cells from an Scl70+ SSc patient suggested that CD19-CAR-T cell therapy reverses adaptive autoimmunity and restores Fcγ-receptor IIIA-expressing innate immune cells by reducing immune complex activity (62).